AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17659770 — intervention group
Group type: EXPERIMENTAL
Intervention: RelyX Unicem (RU) at 37 degrees C
Number of subjects: 40
Study 17659770 — intervention group
Group type: EXPERIMENTAL
Intervention: Panavia F 2.0 (PF) at 4 degrees C
Number of subjects: 40
Study 17659770 — intervention group
Group type: EXPERIMENTAL
Intervention: Panavia F 2.0 (PF) at 24 degrees C
Number of subjects: 40
Study 17659770 — intervention group
Group type: EXPERIMENTAL
Intervention: Panavia F 2.0 (PF) at 37 degrees C
Number of subjects: 40
Study 17659770 — intervention group
Group type: EXPERIMENTAL
Intervention: Panavia F 2.0 (PF) at 60 degrees C
Number of subjects: 40
Study 17659770 — intervention group
Group type: COMPARATOR
Intervention: RelyX Unicem (RU) at refrigerator temperature
Number of subjects: 40
Study 17238412 — intervention group
Group type: EXPERIMENTAL
Intervention: Propbank-based Machine Learning (ML) for annotating abstracts of Randomized Controlled Trials
Number of subjects: 0
Study 17238412 — intervention group
Group type: COMPARATOR
Intervention: Intra-domain (WSJ/WSJ)
Number of subjects: 0
Study 17238412 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross-domain (WSJ/medical abstract)
Number of subjects: 0
Study 15364434 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccination against hepatitis B
Number of subjects: 0
Study 15364434 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 0
Study 11194527 — intervention group
Group type: EXPERIMENTAL
Intervention: Lean fish diet
Number of subjects: 11
Study 11194527 — intervention group
Group type: COMPARATOR
Intervention: Nonfish diet (beef, pork, veal, eggs and milk)
Number of subjects: 11
Study 9024371 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous salbutamol (15 micrograms/kg)
Number of subjects: 29
Study 9024371 — intervention group
Group type: COMPARATOR
Intervention: Control (nebulised salbutamol at 2.5 mg or 5.0 mg, depending on age)
Number of subjects: 29
Study 9024371 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous salbutamol
Number of subjects: 29
Study 9024371 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 29
Study 8295467 — intervention group
Group type: EXPERIMENTAL
Intervention: Active laser treatment (1.2 J/point)
Number of subjects: 33
Study 8295467 — intervention group
Group type: COMPARATOR
Intervention: Inactive laser treatment (0 J/point)
Number of subjects: 33
Study 2950179 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunscreen agent
Number of subjects: 12
Study 2950179 — intervention group
Group type: COMPARATOR
Intervention: Base used in sunscreen preparation
Number of subjects: 12
Study 29498748 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness intervention (Present in the Now - PIN)
Number of subjects: 36
Study 29498748 — intervention group
Group type: COMPARATOR
Intervention: Cognitive activity
Number of subjects: 36
Study 27571499 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintedanib plus docetaxel
Number of subjects: 0
Study 26714891 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural activation
Number of subjects: 166
Study 26714891 — intervention group
Group type: COMPARATOR
Intervention: Self-help attention control
Number of subjects: 166
Study 23884439 — intervention group
Group type: EXPERIMENTAL
Intervention: High ERCC1 expression
Number of subjects: 445
Study 23884439 — intervention group
Group type: EXPERIMENTAL
Intervention: Performance status ≥ 1
Number of subjects: 445
Study 23884439 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of metastatic sites ≥ 2
Number of subjects: 445
Study 23884439 — intervention group
Group type: EXPERIMENTAL
Intervention: Recurrent disease (versus unresectable)
Number of subjects: 445
Study 23884439 — intervention group
Group type: COMPARATOR
Intervention: Molecular factors (ERCC1, thymidylate synthase, dihydropyrimidine dehydrogenase, and others)
Number of subjects: 445
Study 20674829 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination azelastine and fluticasone nasal spray
Number of subjects: 610
Study 20674829 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone nasal spray
Number of subjects: 610
Study 20674829 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelastine nasal spray
Number of subjects: 610
Study 20674829 — intervention group
Group type: COMPARATOR
Intervention: Placebo nasal spray
Number of subjects: 610
Study 18320956 — intervention group
Group type: EXPERIMENTAL
Intervention: Voice simulation experience during orientation
Number of subjects: 94
Study 18320956 — intervention group
Group type: COMPARATOR
Intervention: Orientation without voice simulation experience
Number of subjects: 94
Study 16600232 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture on the day of embryo transfer (ET) (ACU 1 group)
Number of subjects: 273
Study 16600232 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture on the day of ET and again 2 days later (ACU 2 group)
Number of subjects: 273
Study 16600232 — intervention group
Group type: COMPARATOR
Intervention: No acupuncture (control group)
Number of subjects: 273
Study 14522298 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.75% applied in 0.1 mL drops 3 times in the 30 minutes before surgery
Number of subjects: 40
Study 14522298 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.75% applied in 0.1 mL drops 6 times in the 60 minutes before surgery
Number of subjects: 40
Study 14522298 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens of bupivacaine 0.75%
Number of subjects: 40
Study 11089660 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza A outbreak in Building A
Number of subjects: 721
Study 11089660 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza A outbreak in Building B
Number of subjects: 721
Study 11089660 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza A outbreak in Building C
Number of subjects: 721
Study 9739895 — intervention group
Group type: EXPERIMENTAL
Intervention: Pristinamycin (1 g b.i.d. for 10 days)
Number of subjects: 293
Study 9739895 — intervention group
Group type: COMPARATOR
Intervention: Oxacillin (1 g b.i.d. for 10 days)
Number of subjects: 293
Study 9739895 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 293
Study 8257472 — intervention group
Group type: EXPERIMENTAL
Intervention: Early amniotomy
Number of subjects: 925
Study 8257472 — intervention group
Group type: COMPARATOR
Intervention: Conservative management
Number of subjects: 925
Study 8257472 — intervention group
Group type: COMPARATOR
Intervention: Early amniotomy and Conservative management
Number of subjects: 925
Study 3516619 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment with azathioprin and steroids (Group A)
Number of subjects: 141
Study 3516619 — intervention group
Group type: COMPARATOR
Intervention: Antilymphocyte globulin (ALG) for three weeks plus azathioprin and steroids (Group B)
Number of subjects: 141
Study 3516619 — intervention group
Group type: COMPARATOR
Intervention: ALG-azathioprin-steroid administration for a mean of nine days followed by ciclosporin (Group C)
Number of subjects: 141
Study 31252303 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 IU oxytocin
Number of subjects: 180
Study 31252303 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study 29165732 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (20 mg/d)
Number of subjects: 0
Study 29165732 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26246320 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy dietary pattern (high scores on the healthy DP) with low energy intake (less than the median)
Number of subjects: 2796
Study 26246320 — intervention group
Group type: EXPERIMENTAL
Intervention: Western dietary pattern
Number of subjects: 2796
Study 26246320 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy dietary pattern (high scores on the healthy DP) with high energy intake (greater than or equal to the median)
Number of subjects: 2796
Study 22946618 — intervention group
Group type: EXPERIMENTAL
Intervention: Bonded hygienic expanders
Number of subjects: 22
Study 22946618 — intervention group
Group type: COMPARATOR
Intervention: Banded hyrax expanders
Number of subjects: 22
Study 21518946 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline for 4 weeks before the target quit date (TQD)
Number of subjects: 101
Study 21518946 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 3 weeks before the TQD, followed by varenicline for 1 week before the TQD
Number of subjects: 101
Study 21518946 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline for 4 weeks before the TQD
Number of subjects: 101
Study 19531608 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral training (n=12)
Number of subjects: 24
Study 19531608 — intervention group
Group type: COMPARATOR
Intervention: Unilateral training (n=12)
Number of subjects: 24
Study 16510862 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified, multicomponent geriatric treatment
Number of subjects: 174
Study 16510862 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 174
Study 14640836 — intervention group
Group type: COMPARATOR
Intervention: Auditory interlingual homophones
Number of subjects: 0
Study 14640836 — intervention group
Group type: COMPARATOR
Intervention: Visual lexical decision times for monolingual controls
Number of subjects: 0
Study 14640836 — intervention group
Group type: COMPARATOR
Intervention: Interlingual homophones with auditory counterparts
Number of subjects: 0
Study 14640836 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublexical cues
Number of subjects: 0
Study 10955790 — intervention group
Group type: EXPERIMENTAL
Intervention: docetaxel
Number of subjects: 134
Study 10955790 — intervention group
Group type: COMPARATOR
Intervention: sequential methotrexate and 5-fluorouracil (MF)
Number of subjects: 134
Study 9088820 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-operative oral diazepam
Number of subjects: 0
Study 9088820 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacral epidural (caudal) block
Number of subjects: 0
Study 9088820 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments together
Number of subjects: 0
Study 9088820 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 8225043 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocolytic and antibiotic therapy
Number of subjects: 81
Study 8225043 — intervention group
Group type: COMPARATOR
Intervention: Nontreated group
Number of subjects: 81
Study 3513012 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate and cyclosporine
Number of subjects: 93
Study 3513012 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine alone
Number of subjects: 93
Study 31447072 — intervention group
Group type: EXPERIMENTAL
Intervention: AVF surgical creation with placement of the VasQ implant
Number of subjects: 40
Study 31447072 — intervention group
Group type: COMPARATOR
Intervention: AVF surgical creation without the implant (control)
Number of subjects: 40
Study 30013378 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% betamethasone valerate and 1% tranilast (B/T)
Number of subjects: 4
Study 30013378 — intervention group
Group type: COMPARATOR
Intervention: 0.1% betamethasone valerate (B)
Number of subjects: 4
Study 26865350 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% D-3-hydroxybutyrate eye drops
Number of subjects: 65
Study 26865350 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 25225151 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Boswellia serrata L. and Cyperus scariosus L. (2g) plus pelvic floor muscle training
Number of subjects: 60
Study 25225151 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus pelvic floor muscle training
Number of subjects: 60
Study 21887727 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg every other week
Number of subjects: 778
Study 21887727 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg weekly
Number of subjects: 778
Study 21887727 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 778
Study 21887727 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab (both dosing regimens)
Number of subjects: 778
Study 20134178 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 mg ropivacaine with 20 microg fentanyl
Number of subjects: 60
Study 20134178 — intervention group
Group type: COMPARATOR
Intervention: 8 mg hyperbaric bupivacaine with 20 microg fentanyl
Number of subjects: 60
Study 16973987 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of montelukast and salmeterol
Number of subjects: 192
Study 15808137 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive education program encouraging providers to lengthen return visit interval
Number of subjects: 0
Study 12225329 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine dihydrochloride (HDC) in combination with IFN-alpha-2b, 3 MIU, three times weekly via subcutaneous injection, with HDC doses of 1 mg either once a day, three times a week; once a day, five times a week; twice a day, three times a week; or twice a day, five times a week.
Number of subjects: 0
Study 12225329 — intervention group
Group type: EXPERIMENTAL
Intervention: HDC + IFN-alpha-2b
Number of subjects: 0
Study 12623386 — intervention group
Group type: COMPARATOR
Intervention: Stenting (2 vessel disease)
Number of subjects: 1205
Study 12623386 — intervention group
Group type: COMPARATOR
Intervention: Stenting (3 vessel disease)
Number of subjects: 1205
Study 12623386 — intervention group
Group type: COMPARATOR
Intervention: Stenting (2 vessel disease, low-cost estimate)
Number of subjects: 1205
Study 12623386 — intervention group
Group type: COMPARATOR
Intervention: Stenting (3 vessel disease, low-cost estimate)
Number of subjects: 1205
Study 12623386 — intervention group
Group type: COMPARATOR
Intervention: CABG (Control)
Number of subjects: 1205
Study 9799034 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (100 mg daily for 6 months)
Number of subjects: 33
Study 9799034 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin (9 mg daily for 6 months)
Number of subjects: 33
Study 9799034 — intervention group
Group type: COMPARATOR
Intervention: Control (not applicable)
Number of subjects: 33
Study 1989962 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly written reports
Number of subjects: 32
Study 1989962 — intervention group
Group type: EXPERIMENTAL
Intervention: Oil-and-tissue method
Number of subjects: 32
Study 1989962 — intervention group
Group type: COMPARATOR
Intervention: Retrospective reporting
Number of subjects: 32
Study 6638443 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective extradural analgesia maintained throughout labour (Group B)
Number of subjects: 2
Study 6638443 — intervention group
Group type: COMPARATOR
Intervention: Selective extradural analgesia allowed to wear off (Group A)
Number of subjects: 2
Study 30866872 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-component workplace intervention (height-adjustable workstations, emails, education and training sessions, support from team leaders and a workplace champion)
Number of subjects: 84
Study 30866872 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-component workplace intervention
Number of subjects: 84
Study 28327172 — intervention group
Group type: EXPERIMENTAL
Intervention: Guizhifulingwan (GFW)
Number of subjects: 50
Study 28327172 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 23410231 — intervention group
Group type: EXPERIMENTAL
Intervention: DNG/E2V
Number of subjects: 74
Study 23410231 — intervention group
Group type: COMPARATOR
Intervention: LNG/EE
Number of subjects: 74
Study 21544071 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine (20 mg for 7 days)
Number of subjects: 18
Study 21544071 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion (150 mg for 7 days)
Number of subjects: 18
Study 21544071 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 20030543 — intervention group
Group type: EXPERIMENTAL
Intervention: Amber lenses (blue-blocking glasses) worn for 3 hours prior to sleep
Number of subjects: 20
Study 20030543 — intervention group
Group type: COMPARATOR
Intervention: Yellow-tinted glasses (control group, blocking ultraviolet only) worn for 3 hours prior to sleep
Number of subjects: 20
Study 17702699 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba treatment (240 mg daily) during the first 12 weeks and supervised exercise training during the second 12 weeks
Number of subjects: 22
Study 17702699 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment during the first 12 weeks and supervised exercise training during the second 12 weeks
Number of subjects: 22
Study 15198791 — intervention group
Group type: EXPERIMENTAL
Intervention: Total gangliosides in plasma of advanced ovarian cancer patients
Number of subjects: 22
Study 15198791 — intervention group
Group type: EXPERIMENTAL
Intervention: Total gangliosides in ascitic fluid of advanced ovarian cancer patients
Number of subjects: 22
Study 15198791 — intervention group
Group type: EXPERIMENTAL
Intervention: Total gangliosides from primary ovarian cancer cell lines
Number of subjects: 22
Study 11723262 — intervention group
Group type: EXPERIMENTAL
Intervention: Zonisamide 400 mg/d
Number of subjects: 203
Study 11723262 — intervention group
Group type: EXPERIMENTAL
Intervention: Zonisamide 100 mg/d
Number of subjects: 203
Study 11723262 — intervention group
Group type: EXPERIMENTAL
Intervention: Zonisamide 200 mg/d
Number of subjects: 203
Study 11723262 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 203
Study 9160129 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac 30 mg IM every 8 hours
Number of subjects: 100
Study 9160129 — intervention group
Group type: COMPARATOR
Intervention: Metamizol 2 g IM every 8 hours
Number of subjects: 100
Study 7964663 — intervention group
Group type: EXPERIMENTAL
Intervention: Left-looking heads
Number of subjects: 241
Study 7964663 — intervention group
Group type: COMPARATOR
Intervention: Right-looking heads
Number of subjects: 241
Study 7964663 — intervention group
Group type: COMPARATOR
Intervention: Judgments of liking
Number of subjects: 241
Study 3497108 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefaclor
Number of subjects: 213
Study 3497108 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline
Number of subjects: 213
Study 28652127 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intervention (written material, self‐completed registration cards, and messages to mobile telephones)
Number of subjects: 358
Study 28652127 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intervention
Number of subjects: 358
Study 28652127 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 358
Study 27930894 — intervention group
Group type: EXPERIMENTAL
Intervention: i-gel
Number of subjects: 120
Study 27930894 — intervention group
Group type: EXPERIMENTAL
Intervention: CTrach
Number of subjects: 120
Study 27930894 — intervention group
Group type: EXPERIMENTAL
Intervention: sILMA
Number of subjects: 120
Study 24458541 — intervention group
Group type: EXPERIMENTAL
Intervention: Clazosentan
Number of subjects: 1157
Study 24458541 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1157
Study 22362844 — intervention group
Group type: EXPERIMENTAL
Intervention: Selexipag
Number of subjects: 43
Study 22362844 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 19819436 — intervention group
Group type: EXPERIMENTAL
Intervention: High-isoflavone soy protein isolate (high-iso SPI; 61.7 ± 7.35 mg isoflavones/day)
Number of subjects: 100
Study 19819436 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-isoflavone soy protein isolate (low-iso SPI; 1.64 ± 0.19 mg isoflavones/day)
Number of subjects: 100
Study 19819436 — intervention group
Group type: COMPARATOR
Intervention: Milk protein isolate (MPI)
Number of subjects: 100
Study 18502358 — intervention group
Group type: EXPERIMENTAL
Intervention: Dead Space (DS) group
Number of subjects: 60
Study 18502358 — intervention group
Group type: COMPARATOR
Intervention: Nondead Space (NDS) group
Number of subjects: 60
Study 15644045 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of 9 MU interferon-alpha2a followed by weekly administration of 180 mug of pegylated interferon-alpha2a/ribavirin for 48 weeks
Number of subjects: 30
Study 15644045 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly administration of 180 mug of pegylated interferon-alpha2a/ribavirin for 48 weeks
Number of subjects: 30
Study 15644045 — intervention group
Group type: EXPERIMENTAL
Intervention: Noncirrhotic patients
Number of subjects: 30
Study 15644045 — intervention group
Group type: EXPERIMENTAL
Intervention: Cirrhotic patients
Number of subjects: 30
Study 12574761 — intervention group
Group type: EXPERIMENTAL
Intervention: Vestibular rehabilitation home program (specific details on dosage and duration not provided)
Number of subjects: 0
Study 12574761 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 10570332 — intervention group
Group type: EXPERIMENTAL
Intervention: Early endoscopy in the emergency department
Number of subjects: 110
Study 10570332 — intervention group
Group type: COMPARATOR
Intervention: Control group (endoscopy in 1 to 2 days)
Number of subjects: 110
Study 8762852 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of IgG in cerebrospinal fluid (CSF)
Number of subjects: 55
Study 8762852 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of anti-mycobacterial antibodies
Number of subjects: 55
Study 8762852 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of IgG or anti-mycobacterial antibodies or both
Number of subjects: 55
Study 8762852 — intervention group
Group type: COMPARATOR
Intervention: Presence of IgG or anti-mycobacterial antibodies in other cases
Number of subjects: 55
Study 1667955 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate
Number of subjects: 20
Study 1667955 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline solution (placebo)
Number of subjects: 20
Study 6389653 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (relocated for nine weeks, managed by geriatrics team)
Number of subjects: 36
Study 6389653 — intervention group
Group type: COMPARATOR
Intervention: Control group (remained in original units, managed by general medical surgical team)
Number of subjects: 36
Study 31185773 — intervention group
Group type: EXPERIMENTAL
Intervention: Neck Group (NG) - observed neck images
Number of subjects: 48
Study 31185773 — intervention group
Group type: COMPARATOR
Intervention: Foot Group (FG) - observed foot images
Number of subjects: 48